Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5

Dawn A. Maier, Andrea L. Brennan, Shuguang Jiang, Gwendolyn K. Binder-Scholl, Gary Lee, Gabriela Plesa, Zhaohui Zheng, Julio Cotte, Carmine Carpenito, Travis Wood, S. Kaye Spratt, Dale Ando, Philip Gregory, Michael C. Holmes, Elena E. Perez, James L. Riley, Richard G. Carroll, Carl H. June, Bruce L. Levine

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

Since HIV requires CD4 and a co-receptor, most commonly C-C chemokine receptor 5 (CCR5), for cellular entry, targeting CCR5 expression is an attractive approach for therapy of HIV infection. Treatment of CD4+ T cells with zinc-finger protein nucleases (ZFNs) specifically disrupting chemokine receptor CCR5 coding sequences induces resistance to HIV infection in vitro and in vivo. A chimeric Ad5/F35 adenoviral vector encoding CCR5-ZFNs permitted efficient delivery and transient expression following anti-CD3/anti-CD28 costimulation of T lymphocytes. We present data showing CD3/CD28 costimulation substantially improved transduction efficiency over reported methods for Ad5/F35 transduction of T lymphocytes. Modifications to the laboratory scale process, incorporating clinically compatible reagents and methods, resulted in a robust ex vivo manufacturing process capable of generating >1010 CCR5 gene-edited CD4+ T cells from healthy and HIV+ donors. CD4+ T-cell phenotype, cytokine production, and repertoire were comparable between ZFN-modified and control cells. Following consultation with regulatory authorities, we conducted in vivo toxicity studies that showed no detectable ZFN-specific toxicity or T-cell transformation. Based on these findings, we initiated a clinical trial testing the safety and feasibility of CCR5 gene-edited CD4+ T-cell transfer in study subjects with HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)245-258
Number of pages14
JournalHuman gene therapy
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5'. Together they form a unique fingerprint.

  • Cite this

    Maier, D. A., Brennan, A. L., Jiang, S., Binder-Scholl, G. K., Lee, G., Plesa, G., Zheng, Z., Cotte, J., Carpenito, C., Wood, T., Kaye Spratt, S., Ando, D., Gregory, P., Holmes, M. C., Perez, E. E., Riley, J. L., Carroll, R. G., June, C. H., & Levine, B. L. (2013). Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Human gene therapy, 24(3), 245-258. https://doi.org/10.1089/hum.2012.172